Evidence map›Paper›PMID 40904676›Full record

ArticleFrontiers in microbiology2025

Epidemiology and outcomes of Carbapenem-resistant Enterobacterales infection in high-risk patients in Saudi Arabia.

Basem M Alraddadi, Emily L G Heaphy, Reem Almaghrabi, Sahar Althawadi, Ahmad M Alshahrani, Salma Almosallam, Abdullah Alraddadi, Lama Hefni, Mooza S Almannaei, Ibrahim Bahabri and 3 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Basem M AlraddadiMedicine Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Emily L G HeaphyResearch-Jeddah Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Reem AlmaghrabiOrgan Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Sahar AlthawadiPathology and Laboratory Medicine Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Ahmad M AlshahraniKing Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Salma AlmosallamMedicine Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Abdullah AlraddadiMedicine Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Lama HefniMedicine Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Mooza S AlmannaeiMedicine Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Ibrahim BahabriMedicine Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Rabab TahaMedicine Department, International Medical Center, Jeddah, Saudi Arabia.
Ebtihal AlamoudiKing Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Mohammed BosaeedMedicine Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Solid organ transplant (SOT) recipients, bone marrow transplant (BMT) recipients, and patients with hematological malignancies experience increased morbidity due to infections caused by multidrug-resistant, Carbapenem-resistant Enterobacterales (CRE). The current study aimed to further describe the epidemiology and outcomes associated with CRE infection in high-risk SOT and BMT recipients and in patients with hematological malignancies in Saudi Arabia. Methods: Patients aged 16 years and older admitted to a participating hospital between October 2018 and August 2024 who received an SOT or a BMT or were diagnosed with a hematological malignancy and had a confirmed CRE infection were included in this retrospective cohort study. A total of 155 eligible patients were included in the study population. The primary outcome of interest was all-cause mortality within 90 days of the date of the first CRE culture. Results: Among the 155 patients, 118 (76.1%) had received a solid organ transplant, while 37 (23.9%) had either a bone marrow transplant or a hematological malignancy. The BMT recipients and patients with hematological malignancies were 2.84 times more likely to die within 90 days of their first positive culture [adjusted odds ratio (AOR) = 2.84, 95% confidence interval (CI) = 1.01-8.01, Conclusion: The BMT recipients and patients with CRE infections harboring the blaOXA-48 gene were at greater risk for 90-day all-cause mortality in Saudi Arabia, confirming previous findings of high mortality rates associated with CRE infections in immunocompromised populations.

Indexed as

bone marrow transplant (BMT)CRE genesEnterobacteralesepidemiologysolid organ transplant (SOT)

Identifiers

PMID40904676
PMCPMC12401997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.